Clinical trials
Brain Neoplasms trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
41 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Active, not recruiting | 4 |
| Unknown status | 4 |
| Recruiting | 3 |
| Terminated | 3 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 6 |
| Medical University of Vienna | 4 |
| MedSIR | 3 |
| Medical University Innsbruck | 3 |
| AbbVie | 2 |
| Bristol-Myers Squibb | 2 |
| Isarna Therapeutics GmbH | 2 |
| NovoCure Ltd. | 2 |
| Activartis Biotech | 1 |
| Celldex Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brain Neoplasms | 41 |
| Glioblastoma | 13 |
| Neoplasms | 8 |
| Breast Neoplasms | 7 |
| Central Nervous System Neoplasms | 6 |
| Glioma | 5 |
| Gliosarcoma | 5 |
| Astrocytoma | 4 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Neoplasm Metastasis | 4 |
Trials
Showing 26 to 41 of 41. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.